Journal Article Review Epublish 32 citations
PubMed: 31936616 DOI: 10.3390/medicina56010024
Challenges and Opportunities in Preclinical Research of Synthetic Cannabinoids for Pain Therapy.
Medicina (Kaunas) 56(1)
Authors: Bogdan Ionel Tamba, Gabriela Dumitrita Stanciu, Cristina Mariana Urîtu, Elena Rezus, Raluca Stefanescu, Cosmin Teodor Mihai, Andrei Luca, Gabriela Rusu-Zota, Maria-Magdalena Leon-Constantin, Elena Cojocaru, Bogdan Gafton, Teodora Alexa-Stratulat
Affiliations
- Center for Advanced Research and Development in Experimental Medicine (CEMEX), "Grigore T. Popa" University of Medicine and Pharmacy, 16 Universitatii Street, 700115 Iasi, Romania.
- Department of Rheumatology and Physiotherapy, "Grigore T. Popa" University of Medicine and Pharmacy, 16 Universității Street, 700115 Iasi, Romania.
- Department of Pneumology, "Grigore T. Popa" University of Medicine and Pharmacy, 16 Universității Street, 700115 Iasi, Romania.
- Pharmacology, Clinical Pharmacology and Algesiology Department, "Grigore T. Popa" University of Medicine and Pharmacy, 16 University Street, 700115 Iasi, Romania.
- Medical Semiology Department, "Grigore T. Popa" University of Medicine and Pharmacy, 16 University Street, 700115 Iasi, Romania.
- Morpho-Functional Sciences Department, "Grigore T. Popa" University of Medicine and Pharmacy, 16 University Street, 700115 Iasi, Romania.
- Medical Oncology-Radiotherapy Department, "Grigore T. Popa" University of Medicine and Pharmacy, 16 University Street, 700115 Iasi, Romania.
Abstract
Cannabis has been used in pain management since 2900 BC. In the 20th century, synthetic cannabinoids began to emerge, thus opening the way for improved efficacy. The search for new forms of synthetic cannabinoids continues and, as such, the aim of this review is to provide a comprehensive tool for the research and development of this promising class of drugs. Methods for the in vitro assessment of cytotoxic, mutagenic or developmental effects are presented, followed by the main in vivo pain models used in cannabis research and the results yielded by different types of administration (systemic versus intrathecal versus inhalation). Animal models designed for assessing side-effects and long-term uses are also discussed. In the second part of this review, pharmacokinetic and pharmacodynamic studies of synthetic cannabinoid biodistribution, together with liquid chromatography-mass spectrometric identification of synthetic cannabinoids in biological fluids from rodents to humans are presented. Last, but not least, different strategies for improving the solubility and physicochemical stability of synthetic cannabinoids and their potential impact on pain management are discussed. In conclusion, synthetic cannabinoids are one of the most promising classes of drugs in pain medicine, and preclinical research should focus on identifying new and improved alternatives for a better clinical and preclinical outcome.
MeSH
Pain, Pharmaceutical Preparations, Pain Management, Analgesia, Research, Therapeutics, Cannabinoids
Cited by
- Tetrahydrocannabinol and Cannabidiol for Pain Treatment-An Update on the Evidence. Biomedicines, 2024
- Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids. Pharmacol Biochem Behav, 2021
- Investigation of Cannabinoid Acid/Cyclodextrin Inclusion Complex for Improving Physicochemical and Biological Performance. Pharmaceutics, 2023
- Medicinal Cannabis and Synthetic Cannabinoid Use. Medicina (Kaunas), 2021
- It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets. Molecules, 2021
- Major Phytocannabinoids and Their Related Compounds: Should We Only Search for Drugs That Act on Cannabinoid Receptors? Pharmaceutics, 2021
- The Roles of Imaging Biomarkers in the Management of Chronic Neuropathic Pain. Int J Mol Sci, 2022
- Bioactive Compound-Based Formulations: New Perspectives for the Management of Orofacial Pain. Molecules, 2023